5,14,15-trihydroxy-6,8,10,12-eicosatetraenoic acid | 92950-25-9

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5,14,15-trihydroxy-6,8,10,12-eicosatetraenoic acid
• 英文别名: (6E,8E,10E,12E)-5,14,15-trihydroxyicosa-6,8,10,12-tetraenoic acid
• CAS: 92950-25-9
• 化学式: C₂₀H₃₂O₅
• 分子量: 352.471
• InChiKey: UXVRTOKOJOMENI-ICTGYCPSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

文献信息

• Compounds and methods for modulating vascular injury
  申请人：The Regents of the University of California

  公开号：US10111847B2

  公开（公告）日：2018-10-30

  Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of vascular smooth muscle cells (VSMC) or vascular endothelial cells (VEC). Pro-resolving lipid mediators that fmd use in the subject methods include derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids, such as resolvins, protectins, lipoxins and maresins and their therapeutically stable analogs. Also provided are vascular devices and compositions for use in the subject methods. Such methods, devices and compositions fmd use in a variety of applications, including applications related to treatment of vascular injuries and vascular scarring (e.g., restenosis), and applications related to chronic inflammatory diseases of the vascular wall.

  本发明提供了调节受试者血管损伤和/或血管瘢痕愈合反应的方法。因此，本公开的各个方面涉及使用促溶解脂质介质来调节血管壁的炎症和/或再狭窄。本公开的另一方面涉及使用促溶解脂质介质调节血管平滑肌细胞（VSMC）或血管内皮细胞（VEC）的生物活性。可用于上述方法的促溶解脂质介质包括欧米伽-3 多不饱和脂肪酸和欧米伽-6 多不饱和脂肪酸的衍生物，如 resolvins、protectins、lipoxins 和 maresins 及其治疗上稳定的类似物。此外，还提供了用于上述方法的血管装置和组合物。这些方法、装置和组合物可用于多种应用，包括与治疗血管损伤和血管瘢痕（如再狭窄）有关的应用，以及与血管壁慢性炎症性疾病有关的应用。
• Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities
  申请人：——

  公开号：US20040132820A1

  公开（公告）日：2004-07-08

  The present invention relates to the use of the antiviral activity of exogenous leukotriene B 4 (LTB 4 ), variants and derivatives thereof as a therapeutic agent in viral infections caused by human and animal viruses. The present invention also relates to the use of LTB 4 as an anti-neoplastic agent in the prophylaxis and treatment of cancers induced by tumor viruses and in other neoplasic diseases. The human and animal viruses are DNA viruses, such as parvoviridae, papovaviridae, adenoviridae, herpesviridae, poxyviridae and hepadnaviridae; RNA viruses, such as picornaviridae, togaviridae, orthomyxoviridae, paramyxoviridae, coronaviridae, reoviridae, and filoviridae in general, and Retroviridae such as HIV-1 and HIV-2.

  本发明涉及利用外源性白三烯 B 4 (LTB 4 )、其变体和衍生物的抗病毒活性作为人类和动物病毒引起的病毒感染的治疗剂。本发明还涉及使用 LTB 4 作为抗肿瘤剂，用于预防和治疗由肿瘤病毒诱发的癌症和其他肿瘤性疾病。人类和动物病毒包括 DNA 病毒，如副病毒科、乳头瘤病毒科、腺病毒科、疱疹病毒科、poxyviridae 和 hepadnaviridae；RNA 病毒，如 picornaviridae、togaviridae、orthomyxoviridae、paramyxoviridae、coronaviridae、reoviridae 和 filoviridae，以及逆转录病毒科，如 HIV-1 和 HIV-2。
• In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
  申请人：Gosselin Jean

  公开号：US20050239889A1

  公开（公告）日：2005-10-27

  The invention relates to the in vivo release of endogenous anti-microbial mediators using leukotriene B4 administration. The present invention furthermore relates to the use of leukotriene B4 for the treatment and/or prophylaxis of diseases that are positively influenced by such anti-microbial mediators.

  本发明涉及使用白三烯 B4 在体内释放内源性抗微生物介质。本发明还涉及使用白三烯 B4 治疗和/或预防受此类抗微生物介质积极影响的疾病。
• USE OF LEUKOTRIENE B 4? OR ITS ANALOGUES AS ANTIVIRAL AND ANTINEOPLASTIC AGENTS
  申请人：Virocell Inc.

  公开号：EP0881900A1

  公开（公告）日：1998-12-09
• LTB4 AS VACCINE ADJUVANT
  申请人：Virocell Inc.

  公开号：EP1401492A1

  公开（公告）日：2004-03-31